Aflibercept 23 September 2024 | Positive 52-Week, Ph 3 Results for Celltrion’s Aflibercept Biosimilar On 23 September...
Pearce IP BioBlast® for the week ending 27 September 2024
read more
Pearce IP BioBlast® for the week ending 20 September 2024
Aflibercept 19 September 2024 | EU | Sandoz & Samsung Bioepis/Biogen Aflibercept Biosimilars Recommended in Europe...
Pearce IP BioBlast® for the week ending 13 September 2024
Aflibercept 13 September 2024 | KR | Alteogen Submits Application for Biosimilar Aflibercept in Korea On 13 September...
Pearce IP BioBlast® for the fortnight ending 06 September 2024
Adalimumab 1 September 2024 | AU | Pfizer’s Biosimilar Adalimumab PBS-Listed in Australia On 1 September 2024, the PBS...
Generic Partners & Apotex Infringe valid Neurim Sleep Patent
No Rest For Infringers of Valid Melatonin Patent in Australia
CQMS has successfully opposed ESCO Group’s (ESCO) patent application AU 2018201726 (‘726) on the grounds of lack of support and sufficiency. We previously reported on an opposition between the same parties for a related patent family member AU 2018201710 (‘710). As with that case, the Delegate in the present opposition exercised his authority under section 60(3) of the Patents Act 1990 and raised the additional opposition ground of inutility, which was not asserted by CQMS.
Pearce IP BioBlast® for w/e 16 August 2024
16 August 2024 | AU | Janssen Sues Samsung Bioepis for Patent Infringement in Australian Court On 16 August 2024,...
Pearce IP BioBlast® for w/e 09 August 2024
9 August 2024 | Sandoz Reports Q2/24 and Half Year Financial Results - 37% Biosimilar Growth On 9 August 2024, Sandoz...
Pearce IP BioBlast® for w/e 02 August 2024
2 August 2024 | AU | Novo Nordisk Launches Wegovy® (Semaglutide) in Australia On 2 August 2024, Australia’s...
Pearce IP BioBlast® for w/e 26 July 2024
26 July 2024 | EU | New Indication Alert: EU Approves AbbVie’s Skyrizi® (Risankizumab) for UCOn 26 July 2024, AbbVie...
Pearce IP BioBlast® for w/e 19 July 2024
19 July 2024 | EU | Gedeon Richter’s EU Denosumab Biosimilars AcceptedOn 19 July 2024, Gedeon Richter announced that...
Pearce IP BioBlast for w/e 12 July 2024
12 July 2024 | HK | IS | Approval Alert: Eisai’s Leqembi® (Lecanemab) Approved in Hong Kong and Israel for Alzheimer's...
Pearce IP BioBlast for w/e 05 July 2024
7 July 2024 | IN | Approval Alert: Zydus Life Sciences’ Biosimilar Nivolumab Approved in IndiaOn 7 July 2024, Medical...
Pearce IP BioBlast for fortnight ending 28 June 2024
28 June 2024 | Shanghai Henlius Biotech Completes Phase 1 Trials for Daratumumab Biosimilar Shanghai Henlius Biotech...
Interlocutory injunction Granted to Restrain Alleged Patent Infringement in New Zealand
The High Court of New Zealand is only rarely called on to determine applications for interlocutory injunctions in proceedings alleging patent infringement. The decision in this case was that, despite taking more than a